However, cost-effectiveness analyses investigating the potential impact of SGLT2-I and GLP-1 analogues in preventing ASCVD complications and reducing the overall cost burden on the healthcare systems are still lacking in LMICs (27, 28). Here, GCG is linked to atherosclerosis.